Skip to content
Screener

Alamar Biosciences ALMR Cash & Equivalents

Cash & Equivalents at other companies

BK
BKBK
$9.49B+12.8%
Polaryx Therapeutics, Inc. logo
Polaryx Therapeutics, Inc.PLYX
$3.08M+1,132%
Veradermics logo
VeradermicsMANE
$168.41M+419%
Schering-Plough logo
Schering-PloughSGP
$238.9M+312%
Dollar General logo
Dollar GeneralDG
$1.35B+59.2%
Target logo
TargetTGT
$3.53B+22.4%

Other financials

Income statement

See full
Revenue$26.0M+98.9%
Gross profit$14.5M+126%
Operating income-$12.3M-44.4%
Net income-$21.3M-178%
EPS (diluted)-$1.74-156%

Balance sheet

See full
Total debt$30.6M—
Total equity-$178.1M—
Total assets$186.5M—

Cash flow

See full
Operating cash flow-$20.3M-55.7%
CapEx$600.0K+8.3%
Free cash flow-$20.9M-53.8%

Valuation

See full
Market cap$1.96B+37.6%
Enterprise value$1.93B—

Returns & leverage

See full
Debt / equity-0.2×—
Current ratio5.9×—

Where this comes from

Reported directly by Alamar Biosciences in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Alamar Biosciences’s 10-Q, filed May 8, 2026. Open the filing →

Filed
May 8, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-213424

FAQ

What is Alamar Biosciences's cash & equivalents?
Alamar Biosciences (ALMR) reported cash & equivalents of $64.59M in Q1 2026.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Alamar Biosciences's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude